Medical Information

Lomitamide, as a specific drug for the treatment of homozygous familial hypercholesterolemia (HoFH), has not been listed in Chinese Mainland and has not been included in the medical insurance reimbursement. The following provides a detailed explanation from three aspects: the current market situation, alternative acquisition methods, and medication precautions.

1. Domestic listing situation

(1) Approval status: As of September 2025, Lometapai has not been approved by the National Medical Products Administration (NMPA) of China, and there are no formal sales channels in domestic hospitals and pharmacies.

(2) Medical insurance coverage: This drug is not included in the National Basic Medical Insurance Drug Catalog, and patients need to obtain it in full at their own expense.

2 International Access Channels

(1) Original drug source: It can be obtained through approved regions such as the United States, Europe, or Japan. The product name is Juxtapid and the specifications include 5mg/10mg/20mg capsules.

(2) Price reference: The price for a 20mg * 14 pack in the Japanese market is approximately 111469 US dollars. Please pay attention to the cold chain storage requirements for cross-border transportation.

3 Medication precautions

(1) Indication limitations: Only applicable to adult HoFH patients, and should be used in combination with low-fat diet and other lipid-lowering treatments.

(2) Risk Warning: Regular monitoring of liver function and levels of fat soluble vitamins is necessary. Pregnant women should avoid using this medication and it should be discontinued during lactation.